Dynamic Technology Lab Private Ltd purchased a new position in AbbVie Inc (NYSE:ABBV) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,800 shares of the company’s stock, valued at approximately $276,000.

Several other institutional investors have also made changes to their positions in the business. Tandem Investment Advisors Inc. grew its holdings in shares of AbbVie by 3.3% during the second quarter. Tandem Investment Advisors Inc. now owns 148,606 shares of the company’s stock worth $10,775,000 after buying an additional 4,815 shares in the last quarter. WINTON GROUP Ltd grew its holdings in shares of AbbVie by 48.7% during the second quarter. WINTON GROUP Ltd now owns 146,505 shares of the company’s stock worth $10,623,000 after buying an additional 47,980 shares in the last quarter. North Star Asset Management Inc. grew its holdings in shares of AbbVie by 0.9% during the second quarter. North Star Asset Management Inc. now owns 17,180 shares of the company’s stock worth $1,246,000 after buying an additional 150 shares in the last quarter. GWM Advisors LLC grew its holdings in shares of AbbVie by 45.9% during the second quarter. GWM Advisors LLC now owns 21,049 shares of the company’s stock worth $1,512,000 after buying an additional 6,626 shares in the last quarter. Finally, Strategic Wealth Advisors Group LLC bought a new position in shares of AbbVie during the second quarter worth about $2,011,000. Institutional investors own 69.32% of the company’s stock.

In other AbbVie news, EVP Michael Severino sold 25,633 shares of AbbVie stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total value of $2,427,188.77. Following the completion of the transaction, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at approximately $10,881,964.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Richard A. Gonzalez sold 218,193 shares of AbbVie stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the completion of the transaction, the chairman now directly owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. Insiders sold a total of 268,825 shares of company stock valued at $25,186,090 over the last ninety days. Insiders own 0.23% of the company’s stock.

Shares of AbbVie Inc (NYSE:ABBV) opened at $97.35 on Thursday. The firm has a market capitalization of $153,736.20, a P/E ratio of 18.14, a P/E/G ratio of 1.34 and a beta of 1.52. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. AbbVie Inc has a fifty-two week low of $59.27 and a fifty-two week high of $98.87.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The business had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the firm posted $1.21 EPS. analysts predict that AbbVie Inc will post 5.55 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.92%. AbbVie’s payout ratio is currently 62.29%.

A number of research analysts recently issued reports on ABBV shares. Societe Generale increased their price objective on AbbVie in a report on Tuesday, November 21st. Jefferies Group restated a “buy” rating and issued a $107.00 price target (up from $94.00) on shares of AbbVie in a research note on Friday, September 15th. Piper Jaffray Companies restated a “buy” rating and issued a $100.00 price target on shares of AbbVie in a research note on Friday, September 15th. SunTrust Banks restated a “buy” rating and issued a $95.00 price target on shares of AbbVie in a research note on Wednesday, September 13th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $100.00 price target (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $97.96.

ILLEGAL ACTIVITY NOTICE: “Dynamic Technology Lab Private Ltd Takes $276,000 Position in AbbVie Inc (ABBV)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/14/dynamic-technology-lab-private-ltd-takes-276000-position-in-abbvie-inc-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related stocks with our FREE daily email newsletter.